{"id":"W2550582210","doi":"10.1182/blood.v120.21.4029.4029","title":"A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Adverse effect; Internal medicine; Antibody; Toxicity; Multiple myeloma; Gastroenterology; Oncology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067858,0.001447495,0.001868435,0.0005402224,0.0003764679,0.0008232371,0.0009561718,0.001022473,0.002103733],"category_scores_gemma":[0.0008934435,0.0006128399,0.001133391,0.000435163,0.0009733485,0.0008277943,0.0003325609,0.003228595,0.0007064245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001030907,"about_ca_system_score_gemma":0.001250234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009416151,"about_ca_topic_score_gemma":0.001367106,"domain_scores_codex":[0.999562,0.0002034446,0.00001809468,0.00008002727,0.00004051568,0.00009598218],"domain_scores_gemma":[0.9992763,0.0001291383,0.0001772423,0.00008787116,0.00003581647,0.0002935149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5240398,0.1077877,0.01011571,0.0007752375,0.001562426,0.0005656456,0.0009068041,0.008391187,0.1765512,0.0005774145,0.005002983,0.1637239],"study_design_scores_gemma":[0.1934727,0.7722304,0.01319984,0.00002760518,0.0004674833,0.0004505578,0.00008901439,0.001906921,0.01446251,0.0002822939,0.003364687,0.00004595577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953325,0.0009335256,0.0006672405,0.0001838026,0.00004525936,0.001134432,0.0005324788,0.0001043273,0.001066411],"genre_scores_gemma":[0.9945403,0.0007353921,0.001139495,0.0002609956,0.00008742317,0.001181364,0.000860841,0.00003844681,0.00115585],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002103733,"threshold_uncertainty_score":0.007479787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01670394379738835,"score_gpt":0.3009600301493398,"score_spread":0.2842560863519514,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}